RAS Oncology Catalysts Will Drive A Transformational Long Term Opportunity

Catalysts

About Revolution Medicines

Revolution Medicines focuses on targeted therapies for cancers driven by RAS mutations, with a broad portfolio of RAS(ON) inhibitors across multiple tumor types.

What are the underlying business or industry changes driving this perspective?

• The shift toward targeted oncology treatments for RAS driven cancers, such as pancreatic, lung and colorectal tumors, aligns with Revolution Medicines' focused RAS(ON) portfolio, which could support future revenue growth as more indications are addressed.
• A large late stage clinical footprint, including 8 ongoing or planned Phase III registrational trials and more than 2,500 patients treated, positions the company to potentially convert its pipeline into commercial products across several tumor types, which could be important for future revenue and earnings scale.
• Multiple FDA breakthrough therapy designations and the commissioner's national priority voucher for daraxonrasib highlight regulatory recognition of unmet need in RAS driven cancers, which may help compress time from data to potential approvals and impact the timing of revenue and margin progression.
• The trend toward combination regimens in oncology, reflected in partnerships with Tango Therapeutics, Bristol Myers Squibb and Summit Therapeutics, creates opportunities to embed RAS(ON) drugs into multi drug backbones, which could support both pricing power and longer treatment durations that affect net margins and earnings.
• A strong capital position with US$2.03b in cash and investments and access to up to US$2b from Royalty Pharma gives the company room to fund extensive clinical and commercial build out without relying solely on near term revenue, which can influence future earnings potential once operating expenses stabilize.
• Growing emphasis on earlier line and potentially curative settings, such as adjuvant pancreatic cancer and first line use in non small cell lung cancer and pancreatic cancer, expands the addressable patient pool and duration of therapy, which could have a meaningful impact on long term revenue and operating leverage.

Assumptions

This narrative explores a more optimistic perspective on Revolution Medicines compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• Revolution Medicines currently has no revenue. The bullish analysts are forecasting revenue to reach $2.1 billion by March 2029.
• As a pre-revenue company, The bullish analysts expect Revolution Medicines to achieve a profit margin of 20.0% in 3 years time.
• The bullish analysts expect earnings to reach $424.4 million (and earnings per share of $1.93) by about March 2029, up from -$1.1 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $-1.8 billion.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 117.4x on those 2029 earnings, up from -17.7x today. This future PE is greater than the current PE for the US Biotechs industry at 21.2x.
• The bullish analysts expect the number of shares outstanding to grow by 6.39% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.1%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The company is still pre revenue while R&D and commercial spending are large and guided to GAAP operating expenses of US$1.6b to US$1.7b in 2026. If late stage trials do not lead to approvals on reasonable timelines, extended cash burn could pressure the balance sheet and future earnings.
• The entire pipeline is concentrated in RAS driven cancers. If long term clinical data reveal resistance, lower than expected benefit or safety challenges for RAS(ON) inhibitors like daraxonrasib and zoldonrasib in pancreatic, lung or colorectal cancer, the addressable opportunity could be smaller than hoped, which would weigh on revenue and margin potential.
• Revolution Medicines is running multiple large, global, event driven Phase III programs at once. Operational risks such as slower enrollment, complex trial designs, crossover effects or protocol changes could delay or complicate readouts, which may push out potential commercialization and affect the timing of revenue and earnings.
• The company is hiring commercial leadership, building field sales teams and expanding global capabilities ahead of any approved product. If eventual adoption is slower or more limited than internal expectations once a drug is approved, fixed commercial and G&A costs could keep net margins under pressure even as revenue begins.
• Several RAS(ON) programs rely on combination regimens with chemo, PD 1 antibodies, PRMT5 inhibitors and other agents from partners such as Summit, Tango and Bristol Myers Squibb. Shifts in standard of care, competing regimens or partner priorities could limit the role of these combinations and reduce the expected contribution to long term revenue and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Revolution Medicines is $170.0, which represents up to two standard deviations above the consensus price target of $129.35. This valuation is based on what can be assumed as the expectations of Revolution Medicines's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $170.0, and the most bearish reporting a price target of just $73.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $2.1 billion, earnings will come to $424.4 million, and it would be trading on a PE ratio of 117.4x, assuming you use a discount rate of 7.1%.
  
• Given the current share price of $101.19, the analyst price target of $170.0 is 40.5% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.